Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

Submitted by admin on January 8, 2023 - 10:04pm
Source: 
BioPharma Dive
News Tags: 
Eisai
Biogen
drug pricing
Leqembi
Alzheimer's disease
lecanemab
Headline: 
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
snippet: 

The pharma set the average cost of it and Biogen’s newly approved medicine Leqembi to $26,500 per year.

Do Not Allow Advertisers to Use My Personal information